The drugmaker’s application follows its Jan. 29 report in which it said the vaccine had a 66 per cent rate of preventing infections in its large global trial.
Johnson & Johnson asks U.S. FDA for emergency authorization of its COVID-19 vaccine
© The Crystal Eyes